Allena Pharmaceuticals Inc logo

ALNA - Allena Pharmaceuticals Inc Share Price

$1.68 0.1  3.1%

Last Trade - 22/01/21

Sector
Healthcare
Size
Small Cap
Market Cap £57.6m
Enterprise Value £42.8m
Revenue £n/a
Position in Universe 4977th / 6626
Bullish
Bearish
Unlock ALNA Revenue
Momentum
Relative Strength (%)
1m +23.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -51.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AllenaPharmaceuticals Inc revenues was not reported. Net lossdecreased 37% to $22.6M. Lower net loss reflects Research &Development - Balancing value decrease of 55% to $12.4M(expense). Basic Earnings per Share excluding ExtraordinaryItems increased from -$1.65 to -$0.79.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALNA Revenue Unlock ALNA Revenue

Net Income

ALNA Net Income Unlock ALNA Revenue

Normalised EPS

ALNA Normalised EPS Unlock ALNA Revenue

PE Ratio Range

ALNA PE Ratio Range Unlock ALNA Revenue

Dividend Yield Range

ALNA Dividend Yield Range Unlock ALNA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALNA EPS Forecasts Unlock ALNA Revenue
Profile Summary

Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company. The Company is focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. It is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its pipeline includes reloxaliase and ALLN-346. Reloxaliase is an oral enzyme therapeutic that is being developed for the treatment of hyperoxaluria. ALLN-346 is designed to be an orally-administered non-absorbed urate-degrading enzyme. ALLN-346 is being developed to degrade urate in the gastrointestinal (GI) tract.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 24, 2011
Public Since November 2, 2017
No. of Shareholders: 20
No. of Employees: 22
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 48,518,925
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALNA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALNA
Upcoming Events for ALNA
Frequently Asked Questions for Allena Pharmaceuticals Inc
What is the Allena Pharmaceuticals Inc share price?

As of 22/01/21, shares in Allena Pharmaceuticals Inc are trading at $1.68, giving the company a market capitalisation of £57.6m. This share price information is delayed by 15 minutes.

How has the Allena Pharmaceuticals Inc share price performed this year?

Shares in Allena Pharmaceuticals Inc are currently trading at $1.68 and the price has moved by -38.02% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Allena Pharmaceuticals Inc price has moved by -46.49% over the past year.

What are the analyst and broker recommendations for Allena Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Allena Pharmaceuticals Inc, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Allena Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Allena Pharmaceuticals Inc next release its financial results?

Allena Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Allena Pharmaceuticals Inc dividend yield?

Allena Pharmaceuticals Inc does not currently pay a dividend.

Does Allena Pharmaceuticals Inc pay a dividend?

Allena Pharmaceuticals Inc does not currently pay a dividend.

When does Allena Pharmaceuticals Inc next pay dividends?

Allena Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Allena Pharmaceuticals Inc shares?

To buy shares in Allena Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Allena Pharmaceuticals Inc?

Shares in Allena Pharmaceuticals Inc are currently trading at $1.68, giving the company a market capitalisation of £57.6m.

Where are Allena Pharmaceuticals Inc shares listed? Where are Allena Pharmaceuticals Inc shares listed?

Here are the trading details for Allena Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALNA
What kind of share is Allena Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Allena Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Allena Pharmaceuticals Inc share price forecast 2021?

Shares in Allena Pharmaceuticals Inc are currently priced at $1.68. At that level they are trading at 0.256% discount to the analyst consensus target price of 0.00.

Analysts covering Allena Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.958 for the next financial year.

How can I tell whether the Allena Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allena Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -16.92%. At the current price of $1.68, shares in Allena Pharmaceuticals Inc are trading at 8.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Allena Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Allena Pharmaceuticals Inc.

Who are the key directors of Allena Pharmaceuticals Inc?

Allena Pharmaceuticals Inc's management team is headed by:

Alexey Margolin - CHM
Louis Brenner - PRE
Robert Alexander - IND
Gino Santini - IND
Edward Wholihan - CFO
Allene Diaz - IND
Andrew Hack - IND
Ann Miller - DRC
Geoffrey Swire - COO
Who are the major shareholders of Allena Pharmaceuticals Inc?

Here are the top five shareholders of Allena Pharmaceuticals Inc based on the size of their shareholding:

Point72 Asset Management, L.P. Hedge Fund
Percentage owned: 8.24% (4.00m shares)
Frazier Healthcare Partners Venture Capital
Percentage owned: 6.86% (3.33m shares)
Third Rock Ventures, LLC Venture Capital
Percentage owned: 5.75% (2.79m shares)
Bessemer Venture Partners Venture Capital
Percentage owned: 4.66% (2.26m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 3.11% (1.51m shares)
Similar to ALNA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.